Fresh Data Pushes Microbiome Pioneer Ferring Closer To Approval Line
RBX2660 Filing Before Year-End
The promise of microbiome-based therapeutics to treat a variety of diseases has become a hot topic and the first to get to market will be targeting Clostridioides difficile infection. Ferring and its subsidiary Rebiotix are in pole position.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: a preview of the ASCO meeting; small biopharma companies thrive in the US; the world’s first positive Phase III data for a microbiome therapy; Adaptimmune’s plans for its T-cell receptor therapy; and Novo looks at semaglutide in early Alzheimer’s.
The public biotech’s first foray into the microbiome started well, but a clinical trial failure followed by a success has now left Seres with both regulatory and commercial issues.
If all goes well, 2020 could see the Swiss firm's Rebiotix subsidiary get a green light from the FDA for its recurrent Clostridioides difficile fecal product.